MYCN and ALK copy number assessment from plasma at diagnosis could also identify patients with possible subclonal amplifications, and this analysis should accompany tumor biopsy analyses to test its clinical predictive power for possible future use in treatment stratification. The gene discussed is ALK; the disease is neoplasm.